- Home
- IKT
as 07-26-2024 3:33pm EST
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | ATLANTA |
| Market Cap: | 13.4M | IPO Year: | 2020 |
| Target Price: | $23.00 | AVG Volume (30 days): | 33.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.34 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.79 - $3.82 | Next Earning Date: | 08-12-2024 |
| Revenue: | $195,980 | Revenue Growth: | 38.08% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Inhibikase Therapeutics Inc. News
IKT Breaking Stock News: Dive into IKT Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s Disease
Business Wire
2 months ago
Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition
GlobeNewswire
2 months ago
Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus
GlobeNewswire
2 months ago
Share buy-back programme - week 23
Simply Wall St.
2 months ago
Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?
Reuters
2 months ago
Japan's service sector mood hits nearly 2-year low in May
AFP
2 months ago
N. Korea sends more balloons as Kim's sister warns of 'new counteraction'
GlobeNewswire
2 months ago
Velcan Holdings: buyback offer of 500 000 shares at Eur 14.5 per share
Compare IKT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IKT Inhibikase Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.